Silicon Compounds in Sponges

A comparative study of the microscopic morphology and chemical characteristics of spicules of Hexactinellids (Hexactinellida) with different structural features of the skeletons, as well as the freshwater Baikal sponge belonging to the class of common sponges (Demospongia), was carried out. The trace element composition of sponge spicules was determined by X-ray fluorescence spectrometry. The spicules of siliceous sponges contain many elements, arranged in decreasing order of concentration: Si, Ca, Fe, Cl, K, Zn, and others. It was shown that the surface layer of sea sponges contains mainly carbon (C), oxygen (O), and to a lesser extent nitrogen (N), silicon (Si), and sodium (Na). The spicules of the studied siliceous sponges can be divided into two groups according to the phase composition, namely one containing crystalline calcium compounds and one without them. Analysis of infrared absorption spectra allows us to conclude that the sponges Euplectella aspergillum, E. suberia and Dactylocalyx sp. contain silica partially bound to the organic matrix, while the silica skeleton of the sponges of the other group (Schulzeviella gigas, Sericolophus sp., Asconema setubalense, Sarostegia oculata, Farrea sp. and Lubomirskia baicalensis sp.) practically does not differ from the precipitated SiO2. This comparative study of the chemical composition of the skeletons of marine Hexactinellids and common freshwater sponge allows us to conclude that there are no fundamental differences in the chemical composition of spicules, and all of them can be used as a starting material for creating new composite silicon–organic functional materials

New paleomagnetic data from Late Neoproterozoic sedimentary successions in Southern Urals, Russia: implications for the Late Neoproterozoic paleogeography of the Iapetan realm

We present the results of paleomagnetic study of Ediacaran sedimentary successions from the Southern Urals. The analysis of the sedimentary rocks of the Krivaya Luka, Kurgashlya and Bakeevo Formations reveal stable mid-temperature and high-temperature remanence components.Mid-temperature components were acquired during Devonian (Bakeevo Formation) and Late Carboniferous–Early Permian remagnetization events. The high-temperature components in Kurgashlya and Bakeevo Formations are interpreted to be primar , because they are supported by a positive conglomerate test (Bakeevo Formation) and magnetostratigraphic pattern (Kurgashlya Formation). Thehigh-temperature component in the Krivaya Luka Formation is interpreted to be a Late Ediacaran overprint. Our new paleomagnetic poles together with some previously published Ediacaran poles from Baltica and Laurentia are used herein to produce a series of paleogeographic reconstructions of the opening of the Iapetus Ocean

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI) : a phase 3, placebo-controlled, randomised trial

Background: Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin. In this trial, we aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor. Methods: The Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) was a phase 3 randomised, double-blinded, placebo-controlled trial, done in 1315 sites in 42 countries. Patients were eligible if 50 years or older, with type 2 diabetes, receiving anti-hyperglycaemic drugs for at least 6 months, with stable coronary artery disease, and one of three other mutually non-exclusive criteria: a history of previous PCI or of coronary artery bypass grafting, or documentation of angiographic stenosis of 50% or more in at least one coronary artery. Eligible patients were randomly assigned (1:1) to either ticagrelor or placebo, by use of an interactive voice-response or web-response system. The THEMIS-PCI trial comprised a prespecified subgroup of patients with previous PCI. The primary efficacy outcome was a composite of cardiovascular death, myocardial infarction, or stroke (measured in the intention-to-treat population). Findings: Between Feb 17, 2014, and May 24, 2016, 11 154 patients (58% of the overall THEMIS trial) with a history of previous PCI were enrolled in the THEMIS-PCI trial. Median follow-up was 3·3 years (IQR 2·8–3·8). In the previous PCI group, fewer patients receiving ticagrelor had a primary efficacy outcome event than in the placebo group (404 [7·3%] of 5558 vs 480 [8·6%] of 5596; HR 0·85 [95% CI 0·74–0·97], p=0·013). The same effect was not observed in patients without PCI (p=0·76, p interaction=0·16). The proportion of patients with cardiovascular death was similar in both treatment groups (174 [3·1%] with ticagrelor vs 183 (3·3%) with placebo; HR 0·96 [95% CI 0·78–1·18], p=0·68), as well as all-cause death (282 [5·1%] vs 323 [5·8%]; 0·88 [0·75–1·03], p=0·11). TIMI major bleeding occurred in 111 (2·0%) of 5536 patients receiving ticagrelor and 62 (1·1%) of 5564 patients receiving placebo (HR 2·03 [95% CI 1·48–2·76], p<0·0001), and fatal bleeding in 6 (0·1%) of 5536 patients with ticagrelor and 6 (0·1%) of 5564 with placebo (1·13 [0·36–3·50], p=0·83). Intracranial haemorrhage occurred in 33 (0·6%) and 31 (0·6%) patients (1·21 [0·74–1·97], p=0·45). Ticagrelor improved net clinical benefit: 519/5558 (9·3%) versus 617/5596 (11·0%), HR=0·85, 95% CI 0·75–0·95, p=0·005, in contrast to patients without PCI where it did not, p interaction=0·012. Benefit was present irrespective of time from most recent PCI. Interpretation: In patients with diabetes, stable coronary artery disease, and previous PCI, ticagrelor added to aspirin reduced cardiovascular death, myocardial infarction, and stroke, although with increased major bleeding. In that large, easily identified population, ticagrelor provided a favourable net clinical benefit (more than in patients without history of PCI). This effect shows that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk